Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Beximco Pharmaceuticals Limited (R2WA.F)

Compare
0.4100
0.0000
(0.00%)
At close: 8:20:02 AM GMT+2
Currency in BDT All numbers in thousands
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
46,341,432.9250
44,391,603.9250
39,266,662.2370
34,669,172.0520
29,493,573.8690
Cost of Revenue
25,528,433.7040
24,757,616.7040
21,961,699.5020
18,848,962.1070
15,570,071.5810
Gross Profit
20,812,999.2210
19,633,987.2210
17,304,962.7350
15,820,209.9450
13,923,502.2880
Operating Expense
11,788,359.2220
11,044,856.2220
10,131,266.6740
8,974,051.8810
7,264,091.5380
Operating Income
9,024,639.9990
8,589,130.9990
7,173,696.0610
6,846,158.0640
6,659,410.7500
Net Non Operating Interest Income Expense
-1,039,732.7230
-1,143,928.7230
-1,280,168.7370
-998,780.1650
-856,307.8600
Pretax Income
8,214,379.9130
7,525,475.9130
6,068,768.9420
6,686,945.0010
6,377,548.1930
Tax Provision
1,820,766.4430
1,658,704.4430
1,544,300.4520
1,688,316.8040
1,211,798.4610
Net Income Common Stockholders
6,353,528.2000
5,829,529.2000
4,614,066.1470
5,123,136.7120
5,127,693.7110
Diluted NI Available to Com Stockholders
6,353,528.2000
5,829,529.2000
4,614,066.1470
5,123,136.7120
5,127,693.7110
Basic EPS
14.25
13.07
10.34
11.48
11.49
Diluted EPS
14.25
13.07
10.34
11.48
11.49
Basic Average Shares
446,112.0890
446,112.0890
446,112.0890
446,266.2640
446,274.4740
Diluted Average Shares
446,112.0890
446,112.0890
446,112.0890
446,266.2640
446,274.4740
Total Operating Income as Reported
9,219,822.9630
8,674,370.9630
7,216,239.9630
6,881,743.9430
6,650,707.3480
Rent Expense Supplemental
--
240,892.5890
212,537.4830
165,852.9450
131,682.8880
Total Expenses
37,316,792.9260
35,802,472.9260
32,092,966.1760
27,823,013.9880
22,834,163.1190
Net Income from Continuing & Discontinued Operation
6,353,528.2000
5,829,529.2000
4,614,066.1470
5,123,136.7120
5,127,693.7110
Normalized Income
6,361,918.3695
5,830,154.0500
4,606,043.6749
5,159,118.8283
5,142,232.3837
Interest Income
36,245.4440
15,773.4440
5,529.5160
3,055.3580
2,377.2860
Interest Expense
1,037,315.0500
1,121,039.0500
1,241,660.4590
925,595.9580
805,873.7020
Net Interest Income
-1,039,732.7230
-1,143,928.7230
-1,280,168.7370
-998,780.1650
-856,307.8600
EBIT
9,251,694.9630
8,646,514.9630
7,310,429.4010
7,612,540.9590
7,183,421.8950
EBITDA
11,267,291.0940
10,640,325.0940
9,370,932.5390
9,279,551.0190
7,387,385.7840
Reconciled Cost of Revenue
25,528,433.7040
24,757,616.7040
21,961,699.5020
18,848,962.1070
15,570,071.5810
Reconciled Depreciation
2,015,596.1310
1,993,810.1310
2,060,503.1380
1,667,010.0600
203,963.8890
Net Income from Continuing Operation Net Minority Interest
6,353,528.2000
5,829,529.2000
4,614,066.1470
5,123,136.7120
5,127,693.7110
Total Unusual Items Excluding Goodwill
-10,779.5130
-801.5130
10,760.7180
-48,135.2930
-17,745.2370
Total Unusual Items
-10,779.5130
-801.5130
10,760.7180
-48,135.2930
-17,745.2370
Normalized EBITDA
11,278,070.6070
10,641,126.6070
9,360,171.8210
9,327,686.3120
7,405,131.0210
Tax Rate for Calcs
0.0002
0.0002
0.0003
0.0003
0.0002
Tax Effect of Unusual Items
-2,389.3435
-176.6630
2,738.2459
-12,153.1767
-3,206.5643
6/30/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade
Waiting for permission
Allow microphone access to enable voice search

Try again.